noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

Genentech Inc.

Results Genentech Inc.

Genentech Inc.

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-Cell Lymphoma

6/20
Genentech Inc.

Genentech Provides Update on Phase III Verona Study

6/16
Genentech Inc.

Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson’s Disease

6/15
Genentech Inc.

Genentech’s Tecentriq Combined With Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer

6/2
Genentech Inc.

New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-Positive Advanced Breast Cancer

5/31
Genentech Inc.

Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis

5/29
Genentech Inc.

New Two-Year Follow-Up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

5/22
Genentech Inc.

FDA Approves Genentech’s Susvimo for Diabetic Retinopathy

5/22
Genentech Inc.

Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination For People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

5/20
Genentech Inc.

Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer

5/12